160 related articles for article (PubMed ID: 12694163)
21. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma.
Kara IO; Sahin B; Gunesacar R; Unsal C
Adv Ther; 2006; 23(4):635-45. PubMed ID: 17050506
[TBL] [Abstract][Full Text] [Related]
22. [Ki-67 proliferative index in non-Hodgkin's lymphoma and its clinical significance].
Li J; Hu R; Liao AJ; Shi HY; Yan W; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):935-9. PubMed ID: 21867618
[TBL] [Abstract][Full Text] [Related]
23. Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
Lal A; Bhurgri Y; Vaziri I; Rizvi NB; Sadaf A; Sartajuddin S; Islam M; Kumar P; Adil S; Kakepoto GN; Masood N; Khurshed M; Alidina A
Asian Pac J Cancer Prev; 2008; 9(3):453-8. PubMed ID: 19004134
[TBL] [Abstract][Full Text] [Related]
24. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Hashimoto N; Kitano M; Kakishita E
Br J Haematol; 2002 Mar; 116(4):796-802. PubMed ID: 11886383
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
[TBL] [Abstract][Full Text] [Related]
28. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis.
Passam FH; Alexandrakis MG; Moschandrea J; Sfiridaki A; Roussou PA; Siafakas NM
Int J Immunopathol Pharmacol; 2006; 19(1):161-70. PubMed ID: 16569354
[TBL] [Abstract][Full Text] [Related]
29. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
30. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
31. Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma.
Gonzalez CL; Medeiros LJ; Jaffe ES
Am J Clin Pathol; 1991 Jul; 96(1):81-9. PubMed ID: 2069139
[TBL] [Abstract][Full Text] [Related]
32. Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma.
Demir I; Akan OY; Bilgir F; Yilmaz I; Bozkaya G; Bilgir O
Ir J Med Sci; 2024 Jun; 193(3):1201-1207. PubMed ID: 38270775
[TBL] [Abstract][Full Text] [Related]
33. Clinical and prognostic analysis of 125 cases of non-Hodgkin's lymphoma.
Liu L; Zhang M; Zou P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):547-50. PubMed ID: 18549626
[TBL] [Abstract][Full Text] [Related]
34. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients.
Soydinc HO; Guney N; Basaran M; Duranyildiz D; Yasasever V
Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525895
[TBL] [Abstract][Full Text] [Related]
36. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
Li D; Li G; Wang B
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
[TBL] [Abstract][Full Text] [Related]
37. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
Urquhart A; Berg R
Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
[TBL] [Abstract][Full Text] [Related]
38. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
39. Haptoglobin-related protein as a serum marker in malignant lymphoma.
Epelbaum R; Shalitin C; Segal R; Valansi C; Arselan I; Faraggi D; Leviov M; Ben-Shahar M; Haim N
Pathol Oncol Res; 1998; 4(4):271-6. PubMed ID: 9887357
[TBL] [Abstract][Full Text] [Related]
40. [Clinical and prognostic analysis of 101 cases of primary gastrointestinal non-Hodgkin's lymphoma].
Song LN; Cen XN; Ou JP; Liang ZY; Qiu ZX; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Yin Y; Sun YH; Liu W; Wang Q; Wang LH; Wang Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):387-91. PubMed ID: 23628038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
